As of November 6, 2026, Edesa Biotech, Inc. is a publicly traded company (Nasdaq: EDSA). The largest holder reporting an active stake on Schedule 13D is Pardeep Nijhawan, the executive officer and a director, at 16.31%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, August 25, 2026).
Is this your company?
About to sign with, pay or invest in Edesa Biotech, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Edesa Biotech, Inc. a real, registered company?
- Edesa Biotech, Inc. files with the SEC under CIK 1540159 (its SEC filings).
- Its shares are listed under the ticker EDSA on Nasdaq (SEC company record).
- Incorporated in A1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Edesa Biotech, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Integrated Core Strategies (US) LLC (filed 2026-11-04).
Who are Edesa Biotech, Inc.'s owners and officers?
Edesa Biotech, Inc.: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-04).
Officers and directors, each with the role and the filing that names them:
- : Director (Form D, 2026-06-26)
- : Executive Officer, Director (Form D, 2026-06-26)
- : Director (Form D, 2026-06-26)
- : Executive Officer (Form D, 2026-06-26)
- : Executive Officer (Form D, 2026-06-26)
- : Director (Form D, 2026-06-26)
- : Director (Form D, 2026-06-26)
- : Director (Form D, 2026-06-26)
- : Director (Form D, 2026-06-26)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-04 | Integrated Core Strategies (US) LLC | 8.7% |
| Schedule 13G, 2026-08-26 | Stonepine Capital Management, LLC | 6.9% |
| Schedule 13D/A, 2026-08-25 | Velan Capital Investment Management LP | 9.99% |
| Schedule 13D/A, 2026-08-25 | Pardeep Nijhawan | 16.31% |
| Schedule 13G, 2026-06-18 | Integrated Core Strategies (US) LLC | 5.4% |
| Schedule 13D/A, 2026-06-16 | Pardeep Nijhawan | 19.99% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 7.2% |
| Schedule 13G, 2026-05-15 | Rubric Capital Management LP | 7.74% |
| Schedule 13G/A, 2026-05-15 | Nantahala Capital Management, LLC | 0% |
| Schedule 13G/A, 2026-05-15 | Stonepine Capital Management, LLC | 0.3% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0% |
| Schedule 13G, 2026-03-16 | Perceptive Advisors LLC | 6.7% |
Questions about who owns Edesa Biotech, Inc.
Who owns Edesa Biotech, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Edesa Biotech, Inc.: Pardeep Nijhawan (16.31%, Schedule 13D/A, filed 2026-08-25), Velan Capital Investment Management LP (9.99%, Schedule 13D/A, filed 2026-08-25), Integrated Core Strategies (US) LLC (8.7%, Schedule 13G/A, filed 2026-11-04), Rubric Capital Management LP (7.74%, Schedule 13G, filed 2026-05-15) and Sirenia Capital Management LP (7.2%, Schedule 13G, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Edesa Biotech, Inc.?
By the share each holder's latest filing reports, the largest holders of Edesa Biotech, Inc. on this page are Pardeep Nijhawan (16.31%), Velan Capital Investment Management LP (9.99%) and Integrated Core Strategies (US) LLC (8.7%).
When did Pardeep Nijhawan buy into Edesa Biotech, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Pardeep Nijhawan on this page is the Schedule 13D/A, filed 2026-06-16, reporting 19.99%; its latest, Schedule 13D/A filed 2026-08-25, reports 16.31%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Edesa Biotech, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Edesa Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Edesa Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Edesa Biotech, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,472,700 shares (15.3% of shares outstanding), 952,272 held directly and 520,428 indirectly (Form 4, 2026-11-05).
- , the president: 291,479 shares (3.0% of shares outstanding) (Form 4, 2026-05-29).
- , the chief financial officer: 129,609 shares (1.3% of shares outstanding) (Form 4, 2026-05-29).
- , a director: 72,131 shares (0.75% of shares outstanding), 71,666 held directly and 465 indirectly (Form 4, 2026-05-29).
- , a director: 49,939 shares (0.52% of shares outstanding), 49,417 held directly and 522 indirectly (Form 4, 2026-05-29).
Shares outstanding: 9,641,031 as of 2026-08-13, from the company's latest SEC cover page.
How much has Edesa Biotech, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-26 | $3.50M | $3.50M |
| Form D, 2025-02-14 | $15M | $15M |
Keep reading
More on Edesa Biotech, Inc. and the records around it.
Edesa Biotech, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
Companies that share a holder
- Velan Capital Master Fund LP also filed stake reports on 2 other companies: Jasper Therapeutics, Inc. (Aug 2026), InspireMD, Inc. (May 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), CalciMedica, Inc. (Aug 2026), AEON Biopharma, Inc. (Jul 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/edesa-biotech-inc